Predict your next investment

Corporation
HEALTHCARE | Drug Development
shangpharma.com

See what CB Insights has to offer

Stage

Take Private | IPO

Total Raised

$35M

About Shanghai ChemPartner Co. Ltd.

Provider of integrated services across the drug discovery and development process to international and Chinese pharmaceutical and biotechnology companies. The company's services consist of discovery chemistry, discovery biology, preclinical development, pharmaceutical development, and biologics services. The services are offered on a full-time-equivalent basis or a fee-for-service basis. The company provides services to over 100 customers, including pharmaceutical and biotechnology companies in the world as well as academic and research institutions in the US and China. [Keyword: CRO]

Shanghai ChemPartner Co. Ltd. Headquarter Location

No. 5 Building, 998 Halei Road Zhangjiang Hi-Tech Park Pudong New Area

Shanghai, 201203,

China

86 21 51320088

Latest Shanghai ChemPartner Co. Ltd. News

ShangPharma Announces Second Milestone in Move to Enter Chinese Capital Market

Jun 19, 2017

Share this article SHANGHAI, June 19, 2017 /PRNewswire/ --  ShangPharma, a leading life science partnering organization providing high-quality and cost-effective drug development and discovery services, technology, and investment for the pharmaceutical and biotechnology industry, announced today the intent to join with Quantum Hi-Tech China Biological Co. Ltd. Quantum, in a press release earlier this week, announced their intent to purchase Shanghai ChemPartner, ShangPharma's Contract Research and Contract Manufacturing Organizations (CRO/CMO). This type of merger approach was addressed in a press release by ShangPharma in March and is part of the company's plans to leverage the capital market in China that has been adopted by several biopharmaceutical industry leaders. "Our team is excited to take another step forward with our plans to list on the Chinese stock exchange. We believe Quantum is the right partner to help Shanghai ChemPartner achieve its vision and goals as a public company. A merger would enable both companies to create more value for shareholders. There is no area of business overlap between the two organizations, and Shanghai ChemPartner will be preserved as a stand-alone CRO/CMO business," stated Michael Hui, Chairman and CEO of ShangPharma. This news follows the corporate restructuring of Shanghai ChemPartner earlier this year. Should the Chinese Regulatory Securities Commission approve the merger, the expected timeline for deal closure would be at the end of 2017. "Shanghai ChemPartner is pleased to have successfully completed a strategic restructuring process, resulting in no functional change to our CRO and CMO businesses. After merger approval, our operational plan is to maintain organizational integrity and remain an autonomous corporate division with our leadership intact. Shanghai ChemPartner's name will remain the same, and we will continue to provide uninterrupted services to our clients with the existing staff, located at the current facilities, under the same leadership. We will continue to invest in our CRO/CMO businesses and increase the breadth and depth of our service offerings to meet the emerging needs of our clients," said Livia Legg, Chief Commercial Officer of Shanghai ChemPartner and General Manager of ChemPartner Corporation (US) and ChemPartner EU. Shanghai ChemPartner , which includes ChemPartner, China Gateway Pharmaceutical Development, China Gateway Biologics, and ChemExplorer, offers a broad range of drug discovery and development capabilities including discovery biologics, discovery chemistry, discovery biology, DMPK, CMC, and biologics manufacturing. Shanghai ChemPartner serves a diverse global client base and has laboratories, business offices, and representatives in the US, Europe, China, and Japan. --- Livia Legg, MS, Chief Commercial Officer, news@chempartner.com     To view the original version on PR Newswire, visit: http://www.prnewswire.com/news-releases/shangpharma-announces-second-milestone-in-move-to-enter-chinese-capital-market-300475445.html SOURCE ShangPharma Corporation

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Shanghai ChemPartner Co. Ltd.

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Shanghai ChemPartner Co. Ltd. is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,238 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Shanghai ChemPartner Co. Ltd. Patents

Shanghai ChemPartner Co. Ltd. has filed 1 patent.

The 3 most popular patent topics include:

  • Autoimmune diseases
  • Clusters of differentiation
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

12/9/2020

Immune system, Immunology, Autoimmune diseases, Clusters of differentiation, Integrins

Application

Application Date

12/9/2020

Grant Date

Title

Related Topics

Immune system, Immunology, Autoimmune diseases, Clusters of differentiation, Integrins

Status

Application

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.